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Objectives. To describe a case of ﬂuvoxamine-induced severe hyponatremia, most likely due to abnormal antidiuretic hormone
excretion (SIADH), and to discuss the implication for maintenance treatments for these patients. Clinical Observations. Although
this syndrome had its incidence most commonly among the elderly, we report a case of severe hyponatremia (serum sodium
<114mmol/L), in a relatively young male. Treatment. Symptoms responded well to IV hyperosmolar sodium and to the
discontinuation of ﬂuvoxamine. This patient was maintained for treatment on an alternative Selective Serotonin Reuptake
Inhibitor (SSRI), Citalopram, without developing recurrence of symptoms. Outcome and Conclusion. Protocols to monitor the
maintenance treatments in high-risk patients may be needed to prevent recurrence of serious complications.
Copyright © 2009 Adel Gabriel. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
SSRIs have gained widespread use in elderly depressed
patients because of their favorable adverse eﬀect proﬁle.
However numerous spontaneous reports of the (SIADH)
have followed the increased use of selective serotonin
reuptake inhibitors (SSRIs), especially among the elderly
population. In a review by Liu et al., 1996, it was explained
that although the published cases are very few, there were
over 703 reported cases to authorities, to agencies, and
to pharmaceutical companies. The majority of cases were
reported with the use of ﬂouxitine in over 75% of cases,
and less commonly with other SSRIs, and most (83%) of
the published cases involved patients with 65 years of age or
more, as compared with 74% of the unpublished cases [1–3].
From reviewing literature, there are only three published
cases, which were caused by ﬂuvoxamine. In these cases,
hyponatremia was severe (Na = 103–112mmol/L), patients
were treated with hypertonic saline infusion, and (SIADH)
deemed as the most likely implicated causative mechanism
[4]. The diagnosis of SIADH in these patients was made
based on hyponatremia, low serum sodium, and high urine
osmolalities. We report here a case of severe hyponatremia,
which was associated with SSRI ﬂuvoxamine administration
in a relatively young male.
2.CaseReport
A 49-year-old male admitted with severely depressed mood.
He was communicating feelings of despair, guilty thoughts,
and suicidal ideas. His symptoms started six months prior
to this presentation after the death of his girl friend. There
were signiﬁcant vegetative symptoms, poor concentration,
and severe anxiety for six months. In his psychiatric
history, he was treated for depression and anxiety, for 3
years previously, with diﬀerent antidepressants including the
tricyclic, clomipramine 75mg a day, without any untoward
side eﬀects, and he has been sober from heavy drinking
for more than 10 years. In his family history, his mother
suﬀered from depression and committed suicide when he
was ﬁve years old. Patient has no history of cardiac, renal,
endocrine, or liver disease. The primary diagnosis of major
depression was conﬁrmed by the MINI screen international
neuropsychiatric interview schedule [5]. Following this hos-
pital admission, clomipramine however was replaced with
ﬂuvoxamine. Fluvoxamine was titrated, with a starting dose
of 50mg, which was increased gradually to 150mg a day.
Ten days after starting ﬂuvoxamine, he developed headaches,
a grand mal seizure, and became lethargic. Lab work
revealed severe hyponatremia (serum sodium 114mmol/L),
serum potassium 3.7mmol/L, and renal functions were2 Case Reports in Medicine
normal. Serum osmolality was 241mmol/Kg and urine
osmolality was 427mmol/Kg, urine sodium 45mmol/L,
and urine potassium 7mmol/L. On admission they were
within normal, complete blood count, liver function tests,
electrocardiography, elecrtoencephalography, and computed
tomography of the head. Fluvoxamine was discontinued,
and patient was placed on free water restriction, and
hyperosmolar sodium infusion. Serum sodium returned to
139–141mmol/L over the following four days, and patient’s
mental status improved gradually. Fluvoxamine was replaced
by citalopram, which was increased gradually to 60mg/day.
Serum sodium remained stable within normal range for the
8 months following hospital discharge. During this period,
sodium was monitored once on a daily basis for one week,
then once weekly for another month and fortnightly for six
months. No recurrence of hyponatremia was reported in this
case.
3. LiteratureReview
Christensen et al. (1996) described three cases of hypona-
traemia/syndrome of inappropriate secretion of antidiuretic
hormone associated with Fluoxetine, paroxetine, and Citalo-
pram, in three elderly women which improved with the
discontinuation of the drugs and ﬂuid restriction [6].
Masood et al. described a patient with hyponatremia
associated with venlafaxine therapy [7] ,a n dO d e he ta l .
(2001) described an elderly woman who presented with
severe symptomatic hyponatremia caused by the SIADH
during therapy with Citalopram [8]. In these reports, a
high incidence was consistently reported among the elderly
12.5%[9].Hyponatremiaandthesyndromeofinappropriate
antidiuretic hormone secretion (SIADH) have been also
associated with several psychotropic drugs, for example,
carbamazepine, neuroleptics, and tricyclic antidepressants.
Although many case reports describe this association, few
report the eﬀect of rechallenge with another SSRI. There
was a case in the literature for an elderly patient who
developed hyponatremia with sertraline and SIADH when
rechallenged with ﬂuoxetine [10], and a case of an 82-
year-old patient who was hospitalised for convulsions ten
days after initiation of ﬂuoxetine therapy for depression.
She had severe hyponatremia and increased urine osmo-
larity suggesting SIADH [11]. Hyponatremia developed
in (12%) of patients after 10 days approximately after
initiation of paroxetine treatment. In this recent longitudinal
study on ambulatory psychogeriatric patients (n = 75,
and mean age 75.3), who received a diagnosis of major
depressive episode, plasma sodium levels were monitored
before initiating paroxetine therapy and after 1, 2, 4, 6,
and 12 weeks of treatment. Lower body mass index and
lower baseline plasma sodium level (<138mmol/L) were
signiﬁcant risk factors for the development of hyponatremia
[12].
A delayed recurrent hyponatremia, in an elderly patient,
following the replacement of ﬂuvoxamine with paroxetine
wasalsoreported,andauthorssuggestedthatplasmasodium
concentrations must be monitored, not only in the ﬁrst
weeks of treatment, but throughout the full course [13].
4. Discussion
While SSRIs have been reported to cause SIADH, the actual
incidence remains unclear. From the published case reports,
the elderly may appear to be at higher risk of developing
SIADH. According to symptomatic and laboratory presen-
tation in this patient including lethargy, hyponatremia, the
elevated urinary sodium, the inappropriately hyperosmolar
urine, and the absence of cardiac, renal, endocrine, or liver
disease, SIADH is suspected as contributing cause. Of the
published reports, only three convincingly demonstrated
a causative role of SSRI-induced SIADH by rechallenge.
As a result, the published case reports cannot deﬁnitely
establishacausalrelationship.Physiciansmustrecognizeand
ensurethepropermonitoringparameters,namely,dailyﬂuid
intake, patient weight, and the serum sodium concentrations
[14]. Age-related susceptibility to hyponatraemia may be
explained by physiological changes in renal and endocrine
function. The high prevalence of polymedication and pluri-
pathology in the elderly was suggested by some of the
contributing factors. For example, Rosner (2004) reported
two cases of severe hyponatremia associated with combined
use of thiazide diuretics and selective serotonin reuptake
inhibitors [15]. Before being switched to ﬂuvoxamine, our
patientwasonclomipramine,whichisawell-knowntricyclic
antidepressant with potent SSRI properties. This may have
predisposed him to be more vulnerable to the hyponatremic
eﬀect despite being younger in age group than those who
were reported to suﬀer most.
Protocols for monitored maintenance treatments in
high-risk patients need to be formalized in order to prevent
recurrenceandseriousrenalandneurologicalcomplications.
However, an important question remains to be answered:
shouldmaintenancetreatmentsmonitoringbecomeaformal
process for these patients, how long monitoring should
continue?Thisisveryimportanttoanswerbecauseofthefact
that patients who suﬀer from depression may be switched
from one antidepressant to another for diﬀerent reasons,
including intolerance to side eﬀects, or poor eﬃcacy, and
may need prolonged periods of maintenance of the SSRIs
therapy.
Disclosure
There was no funding from any pharmaceutical company to
support writing this case report. Patient gave an informed
consent to author for this publication.
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